Tech Company Financing Transactions

SynOx Therapeutics Funding Round

On 4/22/2024, SynOx Therapeutics secured $75 million in Series B funding from Bioqube Ventures, Forbion Capital Partners and Healthcap Venture Capital.

Transaction Overview

Company Name
SynOx Therapeutics
Announced On
4/22/2024
Transaction Type
Venture Equity
Amount
$75,000,000
Round
Series B
Investors

Bioqube Ventures (Lead Investor)

Forbion Capital Partners (Lead Investor)

Healthcap Venture Capital (Lead Investor)

Proceeds Purpose
The company intends to use the funds to generate registrational Phase 3 clinical and CMC data for emactuzumab, its potentially best-in-class CSF-1(R) inhibiting monoclonal antibody (mAb) for the treatment of Tenosynovial Giant Cell Tumour (TGCT).

Company Information

Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
3 Dublin Landings, North Wall Quay
Dublin 1, D01 C4E0
Ireland
Phone
Undisclosed
Website
www.synoxtherapeutics.com
Email Address
Not Recorded
Overview
At SynOx, we understand the power of being in control of your own journey in the treatment of your disease. Our mission is to establish emactuzumab as a best-in-class drug of choice to address the unmet needs, and improve the quality of life, of as many patients as possible.
Profile
SynOx Therapeutics LinkedIn Company Profile
Social Media
SynOx Therapeutics Company Twitter Account
Company News
SynOx Therapeutics News
Facebook
SynOx Therapeutics on Facebook
YouTube
SynOx Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chairman
Ton Logtenberg
  Ton Logtenberg LinkedIn Profile  Ton Logtenberg Twitter Account  Ton Logtenberg News  Ton Logtenberg on Facebook
Chief Executive Officer
Ray Barlow
  Ray Barlow LinkedIn Profile  Ray Barlow Twitter Account  Ray Barlow News  Ray Barlow on Facebook
Chief Medical Officer
Hamina Patel
  Hamina Patel LinkedIn Profile  Hamina Patel Twitter Account  Hamina Patel News  Hamina Patel on Facebook
Chief Technical Officer
Broes Naeye
  Broes Naeye LinkedIn Profile  Broes Naeye Twitter Account  Broes Naeye News  Broes Naeye on Facebook
VP - Bus. Development
Sander Veltkamp
  Sander Veltkamp LinkedIn Profile  Sander Veltkamp Twitter Account  Sander Veltkamp News  Sander Veltkamp on Facebook
VP - Finance
Sarah Clare
  Sarah Clare LinkedIn Profile  Sarah Clare Twitter Account  Sarah Clare News  Sarah Clare on Facebook

 

 

Browse more venture capital transactions:

Prev: 4/22/2024: Auxa Health venture capital transaction
Next: 4/22/2024: OnePay venture capital transaction

 

Share this article

 

Where The Data Comes From

We report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.